Sitosterolemia Cell Models for Research

Sitosterolemia (also known as phytosterolemia) is a rare autosomal recessive lipid metabolic disorder characterized by elevated plasma levels of plant sterols (sitosterol, campesterol, stigmasterol) and xanthomas, premature atherosclerosis, and hemolytic anemia. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in 100,000 individuals worldwide (WHO, 2023). The condition is underdiagnosed due to variable clinical presentation and lack of awareness. If untreated, affected individuals may develop severe cardiovascular complications early in life. Early diagnosis and dietary intervention are critical to prevent morbidity and mortality.

Sitosterolemia serves as an excellent model for studying sterol absorption, cholesterol metabolism, and the role of ATP-binding cassette (ABC) transporters in lipid homeostasis. The disease is caused by mutations in either ABCG5 or ABCG8 genes, which encode sterolin-1 and sterolin-2, respectively. These proteins form a heterodimer that transports plant sterols and cholesterol from intestinal enterocytes back into the gut lumen and from hepatocytes into bile. Research on sitosterolemia has provided insights into the molecular mechanisms of sterol transport and has implications for understanding common conditions such as hypercholesterolemia and atherosclerosis. Public datasets, such as those from ClinVar and gnomAD, provide mutation frequencies and clinical annotations, facilitating genotype-phenotype correlation studies. Open questions include the precise regulation of ABCG5/ABCG8 expression and the potential for targeted therapies.

Although sitosterolemia is not a cancer, its molecular pathways are relevant to lipid metabolism and cardiovascular disease. The key pathway involves the intestinal absorption and biliary excretion of sterols. The steps are as follows:

1. Dietary plant sterols are taken up by enterocytes via NPC1L1 (Niemann-Pick C1-Like 1) transporter.

2. Inside the enterocyte, sterols are esterified by ACAT2 (acyl-CoA:cholesterol acyltransferase 2) and packaged into chylomicrons.

3. ABCG5/ABCG8 heterodimer on the apical membrane effluxes unesterified sterols back into the intestinal lumen, limiting absorption.

4. In the liver, ABCG5/ABCG8 mediates biliary secretion of sterols, promoting their elimination.

Loss-of-function mutations in ABCG5 or ABCG8 impair these efflux mechanisms, leading to sterol accumulation in the body.

Data from ClinVar and literature (e.g., Berge et al., 2000; Lu et al., 2001).

Sitosterolemia primarily affects lipid metabolism pathways, but it also influences signaling networks involved in inflammation and atherosclerosis. Key nodes include:

• • Sterol regulatory element-binding proteins (SREBPs): regulate cholesterol synthesis and uptake; altered sterol levels may affect SREBP processing.
• • Liver X receptors (LXRs): nuclear receptors that sense oxysterols and regulate ABCG5/ABCG8 expression; mutations may impair feedback regulation.
• • Inflammatory pathways: elevated sterol levels can activate NF-κB and promote endothelial dysfunction.
• • Bile acid metabolism: altered sterol excretion affects bile acid synthesis and enterohepatic circulation.

Organoids derived from patient intestinal or hepatic tissues can recapitulate sterol transport and are useful for personalized drug testing.

• • Genetically engineered mouse models (GEMMs): Abcg5/Abcg8 knockout mice show elevated plasma sitosterol and develop xanthomas, mimicking human disease.
• • Diet-induced models: Feeding mice high plant sterol diets can induce hypercholesterolemia, but not full sitosterolemia.
• • Rat models: Less common but can be used for mechanistic studies.
• • Patient-derived xenografts (PDX) are not applicable for metabolic disease but can be used for cancer models with ABCG5/ABCG8 mutations if relevant.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise knockouts or knock-ins of ABCG5 or ABCG8 mutations. These models are invaluable for studying the functional consequences of specific variants. For example:

• • ABCG5 knockout cell lines: generated by introducing frameshift mutations in the ABCG5 gene, resulting in loss of protein function. These cells can be used to study sterol accumulation and efflux.
• • ABCG8 knock-in cell lines: introducing a known pathogenic point mutation (e.g., p.Arg389His) allows for allele-specific analysis.

Commercially available, sequence-verified models accelerate research by providing consistent, quality-controlled cells. These models are essential for drug screening, functional validation, and mechanistic studies.

Gene-edited cell lines are used to validate the role of ABCG5/ABCG8 in sterol transport. For example, knocking out ABCG5 in Caco-2 cells leads to increased sitosterol uptake and reduced efflux, confirming the protein's function. Similarly, knock-in of a pathogenic mutation can be used to study the impact on protein localization and activity. These models enable high-throughput screening to identify genetic modifiers.

Isogenic pairs (wild-type vs. knockout) are ideal for drug screening. For sitosterolemia, potential therapeutic targets include NPC1L1 inhibitors (e.g., ezetimibe) and LXR agonists. Gene-edited cells can be used to test the efficacy of compounds that enhance sterol efflux or reduce absorption. Additionally, they can model resistance to therapies by introducing mutations that affect drug binding.

CRISPR screens can identify genes that modulate sterol levels when ABCG5/ABCG8 are deficient. For example, a synthetic lethality screen in ABCG5 knockout cells could reveal genes essential for cell survival under sterol overload, providing potential drug targets. Gene-edited cells also enable the discovery of biomarkers for disease progression and treatment response.